TAK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Takeda Pharmaceutical Co Ltd (TAK) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive news catalysts, and robust technical indicators support this recommendation.
The stock exhibits bullish technical indicators: MACD is positive and contracting (0.0727), RSI is overbought at 84.478, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at R1: 18.304 and R2: 18.635, with support at S1: 17.23 and S2: 16.899.
Takeda's collaboration with Iambic, worth over $1.7 billion, highlights its focus on AI-driven drug discovery, which could significantly reduce R&D timelines and enhance growth.
Strong Q3 financial performance with revenue up 4.16% YoY, net income up 335.66% YoY, and EPS up 337.08% YoY.
Positive sentiment from analysts, with H.C. Wainwright maintaining a favorable view of Takeda's partnered assets and creativity in transactions.
RSI indicates overbought conditions, which may suggest a short-term pullback.
Slight pre-market decline of -1.42%, though this does not overshadow the overall bullish trend.
In Q3 2026, Takeda demonstrated strong financial growth: Revenue increased by 4.16% YoY to 1.19 trillion, net income surged by 335.66% YoY to 103.64 billion, EPS rose by 337.08% YoY to 65.65, and gross margin improved by 5.94% YoY to 54.91%.
Analysts maintain a positive outlook on Takeda's partnerships and pipeline expansion. H.C. Wainwright highlights the depth and breadth of Takeda's assets and its creative approach to transactions, supporting a long-term growth narrative.
